The use of statines in patients with arterial hypertension and chronic heart failure with preserved left ventricular ejection fraction


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The prospective randomized trial included 167 patients with chronic heart failure (CHF) of II-III functional classes with preserved left ventricular ejection fraction (LVEF) against the background of III stage arterial hypertension. In addition to antihypertensive therapy with perindopril and verapamil SR (n=85) or amlodipine (n=82), atorvastatin was prescribed, which was regularly taken by 50.6 and 48.8% of patients, respectively. After 12 months, in each treatment group, the clinical status and quality of life improved, and the distance covered in the 6-minute walk test increased. Patients receiving atorvastatin had significantly reduced N-terminal pro-brain natriuretic peptide levels; there was a tendency to improvement of diastolic LV function. Addition of atorvastatin to the treatment of CHF with preserved LVEF is advisable in connection with the potential opportunity to improve the prognosis of patients.

Толық мәтін

Рұқсат жабық

Авторлар туралы

S. Kanorsky

FSBEI HE “Kuban State Medical University" of RMH

Email: kanorskysg@mail.ru
MD, Prof., Head of the Department of Therapy № 2 Krasnodar

A. Sereda

FSBEI HE “Kuban State Medical University" of RMH

Department of Therapy № 2 of the Faculty of Continuing Education and Professional Retraining of Specialists Krasnodar

Әдебиет тізімі

  1. Messerli F.H., Rimoldi S.F., Bangalore S. The Transition From Hypertension to Heart Failure: Contemporary Update. J.A.C.C. Heart Fail. 2017 Jul 6. [Epub ahead of print].
  2. Yamamoto K. Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. Yonago Acta Med. 2017;60:71-6.
  3. Yancy C.W., Jessup M., Bozkurt B., et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J. Am. Coll. Cardiol. 2017 Apr 21.
  4. Ponikowski P., Voors A.A., Anker S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European
  5. Fukuta H., Goto T., Wakami K., Ohte N. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. Int. J. Cardiol. 2016;214:301-6.
  6. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal let ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J. 2007;28:2539-50.
  7. Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A., Waggoner A.D., Flachskampf F.A., Pellikka P.A., Evangelista A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J. Am. Soc. Echocardiogr. 2009;22:107-33.
  8. Lang R.M., Badano L.P., Mor-Avi V., et al. Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016; 37:2129-200.
  9. Канорский С.Г., Середа А.Ф. Сравнение верапамила и амлодипина при лечении больных с хронической сердечной недостаточностью и сохраненной фракцией выброса левого желудочка. Кардиология. 2016;12:27-32.
  10. Hung M.J., Cherng W.J., Kuo L.T., Wang C.H. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int. J. Clin. Pract. 2002;56:57-62.
  11. Patel K., Fonarow G.C., Ahmed M., Morgan C., Kilgore M., Love T.E., Deedwania P., Aronow W.S., Anker S.D., Ahmed A. Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction. Circ. Heart Fail. 2014;7:945-52.
  12. Jhund P.S., Anand I.S., Komajda M., Claggett B.L., McKelvie R.S., Zile M.R., Carson P.E., McMurray J.J. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study. Eur. J. Heart Fail. 2015;17:809-17.
  13. Catapano A.L., Graham I., De Backer G., et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J. 2016;37:2999-3058.
  14. Oesterle A., Laufs U., Liao J.K. Pleiotropic Effects of Statins on the Cardiovascular System. Circ. Res. 2017;120:229-43.
  15. Kudo S., Satoh K., Nogi M., et al. SmgGDS as a Crucial Mediator of the Inhibitory Effects of Statins on Cardiac Hypertrophy and Fibrosis: Novel Mechanism of the Pleiotropic Effects of Statins. Hypertension. 2016;67:878-89.
  16. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 2007;357:2248-61.
  17. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet. 2008;372:1231-39.
  18. Bonsu K.O., Reidpath D.D., Kadirvelu A. Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials. Cardiovasc. Drugs Ther. 2016; 30:177-88.
  19. Takano H., Mizuma H., Kuwabara Y., et al. Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ. J. 2013;77:917-25.
  20. Kihara Y. Statin therapy in chronic heart failure: frog prince or bare frog? Circ. J. 2013; 77:895-97.
  21. Silva S., Lourenço P., Paulo C., Ferreira E., Lebreiro A., Sousa A., Mascaranhas J., Patacho M., Araujo J.P., Bettencourt P. Statin-induced low cholesterol is not associated with poor outcome in chronic heart failure. J. Cardiovasc. Pharmacol. Ther. 2012;17:284-90.
  22. Liu G., Zheng X.X., Xu Y.L., Ru J., Hui R.T., Huang X.H. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am. J. Cardiol. 2014;113:1198-204.
  23. Alehagen U., Benson L., Edner M., Dahlström U., Lund L.H. Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of i>50. Circ. Heart Fail. 2015;8:862-70.
  24. Nochioka K., Sakata Y., Miyata S., Miura M., Takada T., Tadaki S., Ushigome R., Yamauchi T., Takahashi J., Shimokawa H. Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ. J. 2015;79:574-82.
  25. Castro P.F., Miranda R., Verdejo H.E., et al. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity. J. Heart Lung Transplant. 2008;27:435-41.
  26. Bielecka-Dabrowa A., Goch J.H., Mikhailidis D.P., Rysz J., Maciejewski M., Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med. Sci. Monit. 2009;15:MS12-23.
  27. Kelly J.P., Dunning A., Schulte P.J., et al. Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. J.A.C.C. Heart Fail. 2016;4:617-24.
  28. Lee H.Y., Cho H.J., Kim H.Y., Jeon H.K., Shin J.H., Kang S.M., Baek S.H. Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study. Korean J. Intern. Med. 2014;29:754-63.
  29. Perez A.C., Jhund P., Preiss D., Kjekshus J., McMurray J.J. Effect of rosuvastatin on fatigue in patients with heart failure. J. Am. Coll. Cardiol. 2013;61:1121-22.
  30. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.
  31. Shah S.J., Kitzman D.W., Borlaug B.A., van Heerebeek L., Zile M.R., Kass D.A., Paulus W.J. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation. 2016;134:73-90.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2017

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>